# Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma

> **NCT00546143** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 32 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Omalizumab
- **DRUG:** Omalizumab
- **DRUG:** Omalizumab

## Key facts

- **NCT ID:** NCT00546143
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-08
- **Final completion:** —
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546143, "Safety and Tolerability of Omalizumab in Patients With Mild to Moderate Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00546143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*